How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Endosaccular Flow Disruption Device Market
- By Device Type: Flow Disruptor Coils, Flow Disruptor Stents, Flow Disruptor Mesh Devices, Flow Disruptor Plugs
- By Aneurysm Location: Intracranial Aneurysms, Peripheral Aneurysms, Visceral Aneurysms
- By Aneurysm Morphology: Saccular Aneurysms, Fusiform Aneurysms, Wide-Neck Aneurysms, Narrow-Neck Aneurysms
- By End User: Hospitals, Specialized Neurovascular Centers, Ambulatory Surgical Centers
- By Material Composition: Nitinol-Based Devices, Platinum-Based Devices, Polymer-Coated Devices
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Flow Disruptor Coils leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 275 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Endosaccular Flow Disruption Device Market report
A complete, evidence-based study - 12 chapters and 115 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Device Type 4
Aneurysm Location 3
Aneurysm Morphology 4
End User 3
Material Composition 3
Companies profiled
Medtronic
Stryker Corporation
MicroVention Terumo
Balt Extrusion
Phenox GmbH
Rapid Medical
InNeuroCo
Blockade Medical
Cerus Endovascular
Pulsta
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Stryker Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →MicroVention Terumo
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Balt Extrusion
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Phenox GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Rapid Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →InNeuroCo
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Blockade Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cerus Endovascular
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Pulsta
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,948M by 2033 · 6.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Flow Disruptor Coils43.9
- Flow Disruptor Stents23.5
- Flow Disruptor Mesh Devices20.1
- Flow Disruptor Plugs12.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$995.6M → $1,812M · 7.8%
Europe$693.9M → $1,082M · 5.7%
Asia Pacific$633.6M → $1,081M · 6.9%
Latin America$392.2M → $671.9M · 7.0%
Middle East and Africa$301.7M → $451.0M · 5.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.322026
6.332027
6.352028
6.372029
6.382030
6.382031
6.402032
6.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic23.2
- Stryker Corporation22.8
- MicroVention Terumo7.3
- Balt Extrusion7.9
- Phenox GmbH5.9
- Rapid Medical4.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type29.7%
Aneurysm Location20.6%
Aneurysm Morphology17.4%
End User17.0%
Material Composition15.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.5
- Europe21.2
- Asia Pacific21.2
- Latin America13.2
- Middle East and Africa8.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 99 | 86 | 86 | 90 | 93 | 82 | 89 |
| Stryker Corporation | 87 | 79 | 79 | 72 | 79 | 75 | 79 |
| MicroVention Terumo | 88 | 64 | 78 | 71 | 88 | 63 | 75 |
| Balt Extrusion | 63 | 58 | 67 | 81 | 76 | 59 | 67 |
| Phenox GmbH | 68 | 64 | 52 | 75 | 63 | 77 | 67 |
| Rapid Medical | 52 | 46 | 68 | 68 | 66 | 54 | 59 |
| InNeuroCo | 61 | 48 | 49 | 56 | 48 | 55 | 53 |
| Blockade Medical | 52 | 48 | 38 | 41 | 48 | 44 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Stryker Corporation
- MicroVention Terumo
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Stryker Corporation | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| MicroVention Terumo | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Balt Extrusion | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Phenox GmbH | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Rapid Medical | − | − | ✓ | ◐ | ✓ | − |
| InNeuroCo | ◐ | − | − | ◐ | − | − |
| Blockade Medical | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic89
2Stryker Corporation79
3MicroVention Terumo75
4Balt Extrusion67
5Phenox GmbH67
6Rapid Medical59
7InNeuroCo53
8Blockade Medical45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicStryker Corporation
Challenger3
Strong scale, closing on the leaders.
MicroVention TerumoBalt ExtrusionPhenox GmbH
Contender1
Focused players with pockets of strength.
Rapid Medical
Niche2
Specialists in a single segment or region.
InNeuroCoBlockade Medical
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Device Type in North America, then scale across Endosaccular Flow Disruption Device Market — a $288M beachhead inside a $5.49B market.
Beachhead (SOM)$288Mobtainable near-term
Serviceable (SAM)$1.94Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Flow Disruptor Coils
Best fit — highest urgency & budget in Device Type.
Economic buyer77 fit
Flow Disruptor Stents
Strong fit — clear ROI and a fast path to value.
End user66 fit
Flow Disruptor Mesh Devices
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Aneurysm Location & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Aneurysm Morphology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel30%
Digital / self-serve18%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Endosaccular Flow Disruption Device Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation12%
Closed-won5%
$11.0KCAC
$63KLTV
5.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Endosaccular Flow Disruption Device Market is a resilient opportunity — $2.46B by 2033, compounding at 4.6%.
TAM · 2025$1.72Btoday
TAM · 2033$2.46Bforecast
CAGR4.6%2027–2033
Cumulative$18.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.46BTotal addressable market
SAM$983MServiceable available market
SOM$159MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.6% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.46BLarge & growingTAM by 2033 at 4.6% CAGR
$983MServiceable nowreachable with today’s model
$159MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.92BBear3.0% CAGR
$2.46BBase4.6% CAGR
$3.15BBull6.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Aneurysm Location optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Endosaccular Flow Disruption Device Market — a $10.1B market by 2033. Plan: grow share from 8.8% to 16.6%.
Market size · 2033$10.1Btotal addressable
Market CAGR7.6%2027–2033
Target share16.6%from 8.8% today
Revenue ambition$1.67Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 16.6% | On track |
| Revenue | $804M | $1.67B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.4% | 39.2% | At risk |
| Customer retention | 84.2% | 92.3% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Aneurysm Location capability
A defensible second engine — invest in Aneurysm Location to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Aneurysm Location
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $201M capacity & capability investment
- Greenlight bolt-on M&A in Aneurysm Location
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Endosaccular Flow Disruption Device Market conversation — a $7.18B market you can size, segment and defend in minutes.
Market size · 2033$7.18Btotal opportunity
Growth3.2%CAGR to 2033
Addressable buyers1,047+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 3 mopayback period
$59K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
MedtronicStryker CorporationMicroVention TerumoBalt ExtrusionPhenox GmbHRapid MedicalInNeuroCoBlockade Medical+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Endosaccular Flow Disruption Device Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Endosaccular Flow Disruption Device Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Endorphins Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportEndorectal Balloon Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportEndoproteinase Lys C Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportEndoplasmic Reticulum Isolation Kit Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportEndoparasiticide Market
Market size, share, segmentation and regional forecast.
$524M market · 2025 base year
View reportEndomyxin Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportEndomyocardial Biopsy Forcep Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportEndomucin Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportEndo Motor Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportEndometrial Suction Curettes Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportEndometrial Sampling Cannulae Market
Market size, share, segmentation and regional forecast.
$403M market · 2025 base year
View reportEndometrial Resection Device Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.